Devyser products now available in Peru
Devyser is excited to announce a new partnership with Biotecnomica in Peru! Our products have now been used to improve laboratory workflows in over 60 countries around the world!
Novel Somatic BRCA2 Variant Identified using the Devyser BRCA NGS kit.
In a case study published in Human Genome Variation (Costella et al. 2018), a novel somatic pathogenic variant of the BRCA2 gene was identified using the Devyser BRCA kit for next-generation sequencing (NGS). The paper concludes that the Devyser BRCA kit is able to detect variants at low admixture levels in tissue, simplifying what has …
Novel Somatic BRCA2 Variant Identified using the Devyser BRCA NGS kit. Read More »
Easily identify BRCA1 and BRCA2 genetic mutations
With cancer identified as the leading cause of death in high-income countries, early identification and treatment of cancer, and potential cancer-causing genetic variants, is essential. As the second most common cancer worldwide, and the most frequently diagnosed cancer among women, breast cancer nonetheless has a high survival rate if diagnosed and treated. Read more about …
Easily identify BRCA1 and BRCA2 genetic mutations Read More »
Looking for new colleagues in our R&D Team
Devyser is now searching for 2 new research scientists and a senior scientist to join our research and development team! Do you know a stellar researcher with experience in NGS, qPCR and diagnostics? This could be the role for you! Did you know that Devyser is one of Swedens best workplaces? With a diverse international …
Cancer overtaking heart disease as leading cause of death
Cancer is overtaking heart disease as the leading cause of death, according to a study published recently in The Lancet medical journal. While heart disease remains the overall leading cause globally, the study of nearly 156k participants, across 21 countries over 11 years, has identified a trend that as living conditions improve, cancer begins to …
Cancer overtaking heart disease as leading cause of death Read More »
Devyser in Croatia
From Sweden to sunny Croatia – Devyser products are improving standardised testing in more than 50 countries around the world!
Devyser operating through the summer
It’s summer in Sweden, which means most people are on vacation, enjoying the weather and being outdoors as much as possible. Many businesses shut down completely! But with customers all around the world, Devyser is “shipping” all the way through.
ESHG 2019
It was a great week at #ESHG2019! It was so nice to see so many of our partners and customers in #Gothenburg in our home country Sweden! we hope you enjoyed the city and our Devyser Swedish candy!
CRISPR-Cas9 presents new possibilities for Thalassemia treatment.
The autosomal recessive inherited blood disorder, b-thalassemia, is caused by reduced or absent synthesis of the beta chains of hemoglobin due to mutations within the HBB gene. The severity of the disease depends on the nature of the mutation and whether the mutations are present in heterozygous or homozygous form. Another autosomal recessive inherited hemoglobinopathy …
CRISPR-Cas9 presents new possibilities for Thalassemia treatment. Read More »
Visit us at EFI 2019
Just two weeks to go until this years European Immunogenetics and Histocompatibility Conference in Lisbon, Portugal. Will you be attending? Keep an eye out for the poster presentation “Performance Paramaters of an NGS Product for Chimerism Monitoring” and visit the Devyser stand at booth 13 to find out more about our new product for the …